Safety of esmolol in patients with acute myocardial infarction treated with thrombolytic therapy who had relative contraindications to beta-blocker therapy

Aryan N. Mooss; Daniel E. Hilleman; Syed M. Mohiuddin; Claire B. Hunter

doi:10.1177/106002809402800601

Safety of esmolol in patients with acute myocardial infarction treated with thrombolytic therapy who had relative contraindications to beta-blocker therapy

Aryan N. Mooss, Daniel E. Hilleman, Syed M. Mohiuddin, Claire B. Hunter

Research output: Contribution to journal › Article › peer-review

41 Scopus citations

Abstract

OBJECTIVE: This study was conducted to evaluate the safety of esmolol in 114 patients treated with thrombolytic therapy for acute myocardial infarction who also had relative contraindications to beta-blockade, and the predictive value of patient tolerance to esmolol and subsequent patient tolerance of oral beta-blocker therapy. PATIENTS: One hundred and fourteen patients with myocardial infarction documented by enzyme concentrations and electrocardiographic changes who also had relative contraindications to beta-blockade. METHODS: Esmolol was initiated during acute myocardial infarction for myocardial ischemia (n=88), hypertension (n=13), or supraventricular tachycardia (n=13). Relative contraindications to beta-blocker therapy included either active signs/symptoms of left ventricular dysfunction or a history of congestive heart failure (n=40), a history of chronic obstructive pulmonary disease or asthma (n=31), bradycardia (HR

Original language	English (US)
Pages (from-to)	701-703
Number of pages	3
Journal	Annals of Pharmacotherapy
Volume	28
Issue number	6
DOIs	https://doi.org/10.1177/106002809402800601
State	Published - Jun 1994

All Science Journal Classification (ASJC) codes

Pharmacology (medical)

Access to Document

10.1177/106002809402800601

Fingerprint Dive into the research topics of 'Safety of esmolol in patients with acute myocardial infarction treated with thrombolytic therapy who had relative contraindications to beta-blocker therapy'. Together they form a unique fingerprint.

Cite this

Safety of esmolol in patients with acute myocardial infarction treated with thrombolytic therapy who had relative contraindications to beta-blocker therapy. / Mooss, Aryan N.; Hilleman, Daniel E.; Mohiuddin, Syed M.; Hunter, Claire B.

In: Annals of Pharmacotherapy, Vol. 28, No. 6, 06.1994, p. 701-703.

Research output: Contribution to journal › Article › peer-review

@article{789436914aee40b8b0c8ab04b382fcd2,

title = "Safety of esmolol in patients with acute myocardial infarction treated with thrombolytic therapy who had relative contraindications to beta-blocker therapy",

abstract = "OBJECTIVE: This study was conducted to evaluate the safety of esmolol in 114 patients treated with thrombolytic therapy for acute myocardial infarction who also had relative contraindications to beta-blockade, and the predictive value of patient tolerance to esmolol and subsequent patient tolerance of oral beta-blocker therapy. PATIENTS: One hundred and fourteen patients with myocardial infarction documented by enzyme concentrations and electrocardiographic changes who also had relative contraindications to beta-blockade. METHODS: Esmolol was initiated during acute myocardial infarction for myocardial ischemia (n=88), hypertension (n=13), or supraventricular tachycardia (n=13). Relative contraindications to beta-blocker therapy included either active signs/symptoms of left ventricular dysfunction or a history of congestive heart failure (n=40), a history of chronic obstructive pulmonary disease or asthma (n=31), bradycardia (HR ",

author = "Mooss, {Aryan N.} and Hilleman, {Daniel E.} and Mohiuddin, {Syed M.} and Hunter, {Claire B.}",

year = "1994",

month = jun,

doi = "10.1177/106002809402800601",

language = "English (US)",

volume = "28",

pages = "701--703",

journal = "Annals of Pharmacotherapy",

issn = "1060-0280",

publisher = "Harvey Whitney Books Company",

number = "6",

}

TY - JOUR

T1 - Safety of esmolol in patients with acute myocardial infarction treated with thrombolytic therapy who had relative contraindications to beta-blocker therapy

AU - Mooss, Aryan N.

AU - Hilleman, Daniel E.

AU - Mohiuddin, Syed M.

AU - Hunter, Claire B.

PY - 1994/6

Y1 - 1994/6

N2 - OBJECTIVE: This study was conducted to evaluate the safety of esmolol in 114 patients treated with thrombolytic therapy for acute myocardial infarction who also had relative contraindications to beta-blockade, and the predictive value of patient tolerance to esmolol and subsequent patient tolerance of oral beta-blocker therapy. PATIENTS: One hundred and fourteen patients with myocardial infarction documented by enzyme concentrations and electrocardiographic changes who also had relative contraindications to beta-blockade. METHODS: Esmolol was initiated during acute myocardial infarction for myocardial ischemia (n=88), hypertension (n=13), or supraventricular tachycardia (n=13). Relative contraindications to beta-blocker therapy included either active signs/symptoms of left ventricular dysfunction or a history of congestive heart failure (n=40), a history of chronic obstructive pulmonary disease or asthma (n=31), bradycardia (HR

AB - OBJECTIVE: This study was conducted to evaluate the safety of esmolol in 114 patients treated with thrombolytic therapy for acute myocardial infarction who also had relative contraindications to beta-blockade, and the predictive value of patient tolerance to esmolol and subsequent patient tolerance of oral beta-blocker therapy. PATIENTS: One hundred and fourteen patients with myocardial infarction documented by enzyme concentrations and electrocardiographic changes who also had relative contraindications to beta-blockade. METHODS: Esmolol was initiated during acute myocardial infarction for myocardial ischemia (n=88), hypertension (n=13), or supraventricular tachycardia (n=13). Relative contraindications to beta-blocker therapy included either active signs/symptoms of left ventricular dysfunction or a history of congestive heart failure (n=40), a history of chronic obstructive pulmonary disease or asthma (n=31), bradycardia (HR

UR - http://www.scopus.com/inward/record.url?scp=0028300528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028300528&partnerID=8YFLogxK

U2 - 10.1177/106002809402800601

DO - 10.1177/106002809402800601

M3 - Article

C2 - 7919552

AN - SCOPUS:0028300528

VL - 28

SP - 701

EP - 703

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 6

ER -